$599

FDA Cuts CNPV Program; Blackstone Funds Pfizer’s Obesity Efforts; Berobenatide SUI Study; Orforglipron Approved in China; Zealand and Altimmune Q3 ’26 Earnings; Novo Zenagamtide AMBITION Studies; Novo Partners with DJ Khaled

A series of cardiometabolic-related news items has been observed from FDA, Pfizer, Lilly, Zealand Pharma, Altimmune, and Novo. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here